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Abstract 
 
Objective: Molecular pathways thought to be effective in carcinogenesis in non-small cell lung cancer (NSCLC), 
new agents have developed in cancer cells against specific targets on these molecular pathways.      We wanted to 
determine the genetic mutation analyzes of our patients before treatment begins and to see the genetic mutation data 
of our country. Materials and Methods: The pathology results of 680 patients with NSCLC were evaluated 
(between 2015-2017). Mutation detection and EGFR mutation analysis were performed by real time PCR method. 
For gene translocation detection: by using specific a probe to Anaplastic Lymphoma Kinase (ALK) and ROS1 gene 
molecules, fluorescence in situ hybridization (FISH), ALK and ROS1 gene rearrangement tests were performed. 
Results: 542 patients had adenocarcinoma (79.7%), and 138 patients (21.3%) had non-adeno associated NSCLC 
pathology. The EGFR mutation was found in 651 patients, 75 (11.5%) were positive and were mutant. ALK was 
found to be positive in 11 patients (2.25%) in 488 patients. ROS was evaluated in 393 patients and in 4 patients 
(1.01%) it was evaluated as positive. Conclusion: The most common mutations for adenocarcinoma occur with 
EGFR, ALK, and ROS 1 gene rearrangements. Unlike literature data, we found that 3 mutations were higher than 
the literature in terms of age and smoking rates were higher in cases with EGFR mutation. Genomic examination 
should be performed in non-adeno NSCLC, especially in non-smokers. With high number of cases and having a 
mosaic of the country, our study is important to share.   
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Introduction 
 
Although the current classification of lung cancer, 
which is the most common cause of 
cancerrelateddeaths, is based on small-cell lung cancer 
and non-small cell lung cancer, since the early 2000s, 
molecular pathways thought to be effective in 
carcinogenesis in non-small cell lung cancer (NSCLC) 
and new agents have begun to be developed in cancer 
cells against specific targets on these molecular 
pathways. 
____________________________ 
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The most effective biomarker for targeted therapy in 
advanced NSCLC is changes in somatic genes called 
"driver mutations". These mutations occur in genes that 
encode proteins that play a role in the growth and death 
of the cell. Drive mutations cause transformation in 
normal cells, causing the cell to acquire malignant 
character. In particular, molecular changes such as 
epidermal growth factor receptor (EGFR), anaplastic 
lymphoma kinase (ALK), and 
"protooncogenictyrosine-protein kinase 1 ROS" 
(ROS1) have highly effective pharmacological forms 
in the targeted treatment process, and they have opened 
a new era in the treatment of lung cancer. 
In our study, we thought that starting out by setting the 
target initially would have a positive effect on 
treatment planning and with a multidisciplinary 
approach; we wanted to determine the genetic mutation 
analyzes of our patients before treatment begins and we 
aimed to see how the genetic mutation data of our 
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country (by being both in Asia and in Europe) is in 
relation with the world data[1-3]. 
 
Materials and Methods 
 
The pathology results of 680 patients with NSCLC 
who had referred in 2015-2017 to the University of 
Health Sciences, Dr. LütfiKirdarKartal Training and 
Research Hospital, Department of Radiation Oncology 
were evaluated. 
SPSS program was used for statistical data analysis. 
Mutation detection and EGFR mutation analysis were 
performed by real time PCR method. 
For gene translocation detection: by using specific a 
probe to Anaplastic Lymphoma Kinase (ALK) and 
ROS1 gene molecules, fluorescence in situ 
hybridization (FISH), ALK and ROS1 gene 
rearrangement tests were performed. 
 
Results 
 
542 patients had adenocarcinoma (79.7%), and 138 
patients (21.3%) had non-adeno associated NSCLC 
pathology. The median age was 63 (34-88) years. 538 
of the cases were male (79.1%) and 142 (20.9%) were 
female. In pathological examination; 348 patients were 
examined from lung (51.2%), 66 (9.7%) from 
mediastinal lymph nodes, 22 from pleura (3.2%) and 
others from metastatic sites (35.9%). The EGFR 
mutation was found in 651 patients, 75 (11.5%) were 
positive and were mutant. 
Table-1: EGFR mutations 
ALK was found to be positive in 11 patients (2.25%) in 
488 patients. 
Table-2: ALK mutations 
ROS was evaluated in 393patients and in 4 patients 
(1.01%) it was evaluated as positive. 
 
Table-3: ROS mutations 
In our study: Exon 19 deletion mutation was found as 
49% in 37 patients, Exon 21 L858R mutation was 
found as 27% in 20 patients, Exon 20 in-frame 
mutation was found as 7% in 5 patients, G719 Point 
mutations in Exon 18 was found as 11% in 8 patients 
and S768I mutation in Exon 20 was found as 5% in 4 
patients. 
 Table-1: EGFR mutations 
 
 EGFR mutations 
Total Present Absent P value 
Age 
60> 
60≤ 
652 
248 
404 
 
19 
56 
 
229 
348 
0,016 
Gender 
Male 
Female 
652 
516 
136 
 
31 
44 
 
485 
92 
0,001> 
Smoking Status 
Smokers 
Non-Smokers 
652 
460 
192 
 
64 
11 
 
396 
181 
0,003 
Histology                         
Adenocarcinoma 
Nonadenocarcinoma 
652 
520 
132 
 
72 
3 
 
448 
129 
0,001> 
 
Table-2: ALK mutations 
 ALK mutations 
Total Present Absent P value 
Age 
60> 
60≤ 
488 
188 
300 
 
5 
6 
 
183 
294 
0,76 
Gender 
Male 
Female 
488 
396 
92 
 
7 
4 
 
389 
88 
0,13 
Smoking Status 488   0,001> 
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Smokers 
Non-Smokers 
366 
122 
2 
9 
364 
113 
Histology                         
Adenocarcinoma 
Nonadenocarcinoma 
488 
389 
99 
 
8 
3 
 
381 
96 
0,47 
 
Table-3: ROS mutations 
 ROS mutations 
Total Present Absent P value 
Age 
60> 
60≤ 
393 
156 
237 
 
2 
2 
 
154 
235 
0,65 
Gender 
Male 
Female 
396 
309 
84 
 
3 
1 
 
306 
83 
1 
Smoking Status 
Smokers 
Non-Smokers 
393 
308 
85 
 
2 
2 
 
306 
83 
0,206 
Histology                         
Adenocarcinoma 
Nonadenocarcinoma 
393 
306 
87 
 
1 
3 
 
305 
84 
0,035 
 
 
Conclusion 
 
The most common mutations for adenocarcinoma 
occur with KRAS, EGFR, ALK, and ROS 1 gene 
rearrangements[1-3]. However, since the clinical 
efficacy of targeted therapies for KRAS mutation has 
not been proven, we did not inclued this mutation 
analysis to our study[4]. 
The second most common mutation is the EGFR 
mutation, located at position 12 of the short arm of 
chromosome 7. Prevalence ranges from 10-15% in 
whites and 30-50% in Asians [5-7]. In our study, 
similar proportions of EGFR was studied in 651 
patients; 75(11.5%) were positive and these were 
mutant type. This mutation is often found in the 
adenocancer histology of non smoking female patients 
[7-9]. When the cases that were positive in our study 
were examined, it was determined that the average age 
was 66.7 and it was found to be higher in terms of sex 
at women with a statistically significant level. 
However, unlike the literature, this mutation 
wassurprisingly found more frequent in smokers that 
smoke more than 10 packets/year (p <0.01). 
EGFR mutations typically occur in the receptor 
tyrosine kinase domain, which activates signaling and 
enhances susceptibility to EGFR-TKI such as gefitinab, 
erlotinib. The presence of EGFR tyrosine kinase 
mutations in advanced NSCLC is a good marker for 
EGFR-TKI sensitivity as well as a better prognosis 
[10-11]. EGFR-TKI response rates in EGFR mutated 
NSCLC patients are at least twice as high as those 
obtained with conventional chemotherapy [12-13]. 
Two common EGFR sensitization mutations identified 
are the in-frame deletion in exon 19, which accounts 
for 45% of EGFR mutations in lung cancer, and the 
L858R point mutation in exon 21, which accounts for 
40% of EGFR mutations. The third most common type 
is in-frame insertions in exon 20 and is detected 
between 5-13%. The others include point mutations in 
exon 18 at G719(3%), mutations in exon 21 at L861Q 
(2%) and in-frame insertions in exon 19 (1%) [7,14-
16]. 
In our study, exon 19 deletion mutation rate was 49% 
in 37 patients, exon 21 L858R mutation was 27% in 20 
patients, exon 20 in-frame mutation was 7% in 5 
patients, point mutations in exon 18 at G719 was 11% 
in 8 patients and S768I mutation in exon 20 was 5% in 
4 patients. 
Another mutation, ALK, is located at position 23 of the 
short arm of the 2nd chromosome [17]. It is detected 
between 3-7% in both white and Asian populations of 
NSCLC cases [18,19]. In our study, ALK mutation 
could be studied in 488 patients and found positive in 
11 patients (2.25%), which is lower than the literature 
results. The most common ALK fusion partner 
detected in NSCLC cases is the echinoderm 
microtubule associated protein-like 4 (EML4) gene. 
EML4- ALK fusion can bee observed in; young 
patients who have never smoked, or mild smokers 
under 10 packs/year, and acinar or histological signet 
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ring adenocarcinoma [20,21]. In our study, the mean 
age of the positive cases was 59.8, and similar to the 
literature, there was statistically significant ALK 
positivity was detected in non-smoking cases. Clinical 
trials have shown significant improvement in response 
rate and progression-free survival in patients with 
NSCLC who were detected as crizotinib ALK-positive, 
when compared with standard chemotherapy [22,23]. 
The novel order or fusion proteins of ALK gene in 
tumor cells can be detected by fluorescence in situ 
hybridization (FISH), immunohistochemistry (IHC) 
and reverse transcription polymerase chain reaction of 
cDNA (RT-PCR). The FISH method is the gold 
standard for the identification of patients with ALK-
positive NSCLC. Many multiple monoclonal 
antibodies have been developed which can be used in 
the IHC method. Although it can be considered as a 
screening method to identify ALK positivity, positive 
results need to be confirmed by FISH method [24]. So 
we have also used these valid methods in our study. 
Another mutation we have examined in our study was 
ROS1 proto oncogene, which locates at the 6. 
chromosome in position 22. ROS 1 rearrangement 
leads to the formation of active fusion proteins and is 
observed in 1-2% of NSCLC cases [25,26]. Crizotinib 
showed evidence of in vitro activity and early clinical 
activity in ROS1-rearrangemented NSCLC [27]. 
In our study, ROS1 mutation was evaluated in 393 
patients and in 4 patients (1.01%), it was positive, this 
result is compatible with the literature. ROS 1 
rearrangement is associated with adenocarcinoma and 
is commonly detected in patients younger than 50 years 
old who are non smokers or mild smokers, and this 
mutation is not associated with EGFR, ALK mutation 
[25]. 
In our study, the mean age of positive cases was 53.8 
and it was thought that the result was not statistically 
significant in terms of smoking but it was thought that 
the low number of cases could lead to this result. In 
addition, consistent with the literature, EGFR and ALK 
mutations were found to be negative in ROS 1 positive 
cases. 
All of these mutations are present in adenocancer 
histology as well as in other subtypes. 
For this reason, in our study, out of 138 patients who 
were found to have NSCLC other than adenocancer; 
EGFR was positive in 2(1.4%), ALK was positive in 
3(3%) and ROS was positive in 3(3%) patients. In 
accordance with the literature, these cases consisted of 
non-smokers. For this reason, genomic examination 
should be performed in non-adeno NSCLC, especially 
in nonsmokers. 
The most important limitations of our study are the 
inability to perform the staging and not to study the 
mutations according to the metastases. Since our study 
has aimed to examine the epidemiologic mutation in 
our country, no evaluation was made in terms of 
survey. 
However, we believe that our study is an important 
work in terms of high number of cases investigated and 
so that our hospital is located in İstanbul, the study may 
show the entire mosaic of Turkey by being at the center 
of the country. 
 
Discussion 
 
In our study that evaluated 680 NSCLC patients, As, 
we aim to share the data of Turkey (by being in the 
middle of Asia and Europe) in terms of genetic 
mutations. EGFR mutation frequency in Western 
populations is 10-15%, while in Asian populations this 
rate is 30-50%. Similarly to Europe, we have a rate of 
11.2. In the literature, ROS1 positivity was found to be 
1-2% and ALK positivity was found to be 3-7%. In our 
study, it was 1.01% for ROS1 and 2.25% for ALK. 
Interestingly, unlike literature data, we found that 3 
mutations were higher than the literature in terms of 
age and smoking rates were higher in cases with EGFR 
mutation. 
EGFR mutation, ALK and ROS1 rearrangements are 
the best-defined molecular changes in NSCLC and 
have a target role in therapy. These genomic changes 
should be looked at in all patients with adenocarcinoma 
or NSCLC pathology in order to determine the target 
from the beginning and avoid unnecessary treatment. 
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